# Camilla Languille

> Camilla Languille is a post-ipo equity investor at Mubadala backing Health Care and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Mubadala](https://shizune.co/investors/profile/mubadala-investment-company-e9c0)
- Total investments: 4
- Last investment: Feb 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/camilla-macapili-languille-b250521/?originalSubdomain=ae

Camilla Languille is a post-ipo equity investor at Mubadala focused on Health Care and Medical. Camilla Macapili Languille Head of Pharma & Medtech at Mubadala Investment Company.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 75% |
| Medical | 2 | 50% |
| Biotechnology | 2 | 50% |
| Pharmaceutical | 2 | 50% |
| Software | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 2 | 50% |
| Series D | 1 | 25% |
| Secondary Market | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 50% |
| India | 1 | 25% |
| Germany | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Manipal Hospitals | Manipal Hospitals is part of the Manipal Education and Medical Group (MEMG), which pioneers in the field of education and healthcare delivery.Manipal Hospitals has a special significance in the overall healthcare industry of India and particularly in South India. A social seed sown more than five decades ago is today the country's thirdlargest healthcare group with a network of 15 hospitals and three primary clinics providing comprehensive care that is both curative and preventive in nature for a wide variety of patients not just from India but also from across the globe. |  | Secondary Market | Feb 02, 2024 |  |
| Certara | Certara is the global leader in biosimulation. It accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries. Certara'send-to-end platform includes biosimulation, regulatory science, and market access solutions. It integrates its unique portfolio of software and technology-enabled services spanning discovery to post-approval. | $250M | Post-IPO Equity | Mar 25, 2021 |  |
| Outset Medical | Outset Medical is a pioneering medical technology company that manufactures medical equipment. The company reimagining dialysis for patients and health care providers. The innovative, compact, user-friendly Tablo Hemodialysis System can deliver both acute and chronic dialysis, wherever you need it.Through the versatile, all-in-one TabloHemodialysis System, they are using innovative technology to drive service model innovation, aimed at reducing cost and transforming the patient care experience. The system comes equipped with wireless data, sensor-based automation, and an animated touchscreen to make the system as easy to use as possible. | $132M | Series D | Aug 28, 2018 |  |
| Evotec | Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances,development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased, and comprehensive infrastructure.Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases, and with Celgene in the field of neurodegenerative diseases. | $274.3M | Post-IPO Equity |  |  |

4 of 4 investments shown.

## Co-investors
- [Baxter Ventures](https://shizune.co/investors/profile/baxter-ventures) — VC Fund, 1 deal together
- [CalPERS](https://shizune.co/investors/profile/calpers-2) — VC Fund, 1 deal together
- [Fidelity](https://shizune.co/investors/profile/fidelity-management-and-research-company) — VC Fund, 1 deal together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 1 deal together
- [Partner Fund Management](https://shizune.co/investors/profile/partner-fund-management) — VC Fund, 1 deal together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 1 deal together

## About Mubadala

VC Fund · Abu Dhabi, United Arab Emirates

Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for its shareholder, the Government of Abu Dhabi. Mubadala’s US $229 billion portfolio spans five continents with interests in multiple sectors including aerospace, ICT, semiconductors, metals and mining, renewableenergy, oil and gas, petrochemicals, utilities, healthcare, real estate, pharmaceuticals and medical technology, agribusiness and a global portfolio of financial holdings across all asset classes. Mubadala has offices in Rio de Janeiro, Moscow, New York, and San Francisco, with a joint venture in Hong Kong. Mubadala is a trusted partner, an engaged shareholder and a responsible global company that is committed to world-class standards of governance.

5 contacts available at Mubadala.

| Name | Title | Profile |
| --- | --- | --- |
| Bakheet Al Katheeri | Executive Director | https://shizune.co/investors/profile/dr-bakheet-al-katheeri |
| Camilla Languille | Head of Pharma & Medtech | https://shizune.co/investors/profile/camilla-languille |
| Mats Johansson | Investor | https://shizune.co/investors/profile/mats-johansson |
| Ali Eid Al Mheiri | Executive Director | https://shizune.co/investors/profile/ali-eid-al-mheiri |
| Antoine Bettant | Senior Associate | https://shizune.co/investors/profile/antoine-bettant |

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Camilla Languille invest in?

Camilla Languille invests primarily in Health Care, Medical and Biotechnology startups, most often at Post-IPO Equity and Series D stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Camilla Languille last invest?

The most recent investment recorded for Camilla Languille closed in Feb 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co